News
ALT
3.380
+0.30%
0.010
Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap
Seeking Alpha · 21h ago
Altimmune Insider Makes Bold New Share Grab
TipRanks · 3d ago
Altimmune director John Gill buys 9,200 shares worth $31,348
Reuters · 3d ago
Weekly Report: what happened at ALT last week (0330-0403)?
Weekly Report · 4d ago
Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street
TipRanks · 5d ago
Top Altimmune Insiders Quietly Boost Their Stakes in a Big Way
TipRanks · 04/02 02:05
Altimmune CFO Gregory Weaver acquires $31,499 common shares
Reuters · 04/01 20:06
Altimmune CEO Jerome Durso acquires $0.0 million common shares
Reuters · 04/01 20:06
BUZZ-Eli Lilly rises after US FDA approves weight-loss pill
Reuters · 04/01 16:19
Weekly Report: what happened at ALT last week (0323-0327)?
Weekly Report · 03/30 09:04
Weekly Report: what happened at ALT last week (0316-0320)?
Weekly Report · 03/23 09:04
ALTIMMUNE INC <ALT.O>: TRUIST SECURITIES INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $12
Reuters · 03/19 11:08
U.S. RESEARCH ROUNDUP-Carnival, Five Below, McKesson
Reuters · 03/19 06:52
Altimmune a new buy at Truist on pemvidutide promise
Seeking Alpha · 03/18 21:03
Altimmune initiated with a Buy at Truist
TipRanks · 03/18 20:00
Altimmune Price Target Raised to $25.00/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 03/16 16:27
Altimmune Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/16 16:27
HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25
Benzinga · 03/16 16:17
Altimmune price target raised to $25 from $12 at H.C. Wainwright
TipRanks · 03/16 16:15
Weekly Report: what happened at ALT last week (0309-0313)?
Weekly Report · 03/16 09:04
More
Webull provides a variety of real-time ALT stock news. You can receive the latest news about Altimmune through multiple platforms. This information may help you make smarter investment decisions.
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.